Administration of Donor T Cells With the Caspase-9 Suicide Gene

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2029

Conditions
Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeAcute Myeloid LeukemiaChronic Myelogenous LeukemiaNon Hodgkin LymphomaHemophagocytic LymphohistiocytosisFamilial Hemophagocytic LymphohistiocytosisHemophagocytic SyndromeEpstein Barr Virus InfectionX-linked Lymphoproliferative Disease
Interventions
BIOLOGICAL

iCaspase9-transduced T cells

Patients will receive the T cells between 30 and 90 days following transplantation. The T cells will be infused through a catheter line.

DRUG

AP1903

"AP1903 will be administered if there is development of Grade 1 or greater GvHD.~Dose: 0.4 mg/kg by IV over 2 hours.~Up to 3 additional doses may be administered if the GvHD does not respond or gets worse."

Trial Locations (2)

77030

Texas Children's Hospital, Houston

The Methodist Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER